PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.67%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-2.50%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
1.09%
Positive EBIT growth while META is negative. John Neff might see a substantial edge in operational management.
1.09%
Positive operating income growth while META is negative. John Neff might view this as a competitive edge in operations.
-26.11%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-25.71%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-25.71%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.29%
Share reduction more than 1.5x META's 0.84%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.15%
Diluted share reduction more than 1.5x META's 0.71%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
3.98%
OCF growth at 50-75% of META's 7.39%. Martin Whitman would question if the firm lags in monetizing sales effectively.
31.18%
FCF growth above 1.5x META's 12.38%. David Dodd would verify if the firm’s strategic investments yield superior returns.
973.53%
10Y revenue/share CAGR above 1.5x META's 322.21%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
137.85%
5Y revenue/share CAGR under 50% of META's 322.21%. Michael Burry would suspect a significant competitive gap or product weakness.
54.90%
3Y revenue/share CAGR under 50% of META's 153.95%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
876.53%
10Y OCF/share CAGR above 1.5x META's 329.24%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
139.11%
Below 50% of META's 329.24%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
71.15%
3Y OCF/share CAGR under 50% of META's 192.33%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
644.16%
Net income/share CAGR above 1.5x META's 90.30% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
67.88%
5Y net income/share CAGR at 75-90% of META's 90.30%. Bill Ackman would advocate improvements to match competitor’s profit expansion.
16.21%
Below 50% of META's 88.29%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
2373.53%
Equity/share CAGR of 2373.53% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
164.51%
Equity/share CAGR of 164.51% while META is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
67.91%
Below 50% of META's 408.11%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.97%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-35.93%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.73%
Asset growth well under 50% of META's 4.54%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
3.48%
1.25-1.5x META's 3.03%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-0.04%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-2.13%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-6.75%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.